Domestically developed API meets international compliance standards, addressing global supply chain gaps for pharmaceutical manufacturers

Guangzhou, China – October 24, 2026 – Guangzhou Hanfang Pharmaceutical Company Limited, a core state-owned pharmaceutical enterprise under GPHL, today announced that its high stability medium chain triglyceride (MCT) active pharmaceutical ingredient is now available for global distribution. The product is designed for pharmaceutical, nutraceutical and special medical food manufacturers, with core advantages including consistent purity, low residual solvent levels and compliance with international pharmacopeia standards. As a domestically developed alternative to previously imported MCT, the product addresses long-standing supply chain gaps for global clients, supporting the expansion of the company in the global medicinal lipid market. Qualified orders are eligible for immediate shipment from the production base of the company in Guangzhou。

Core Technology and Product Highlights

The high stability MCT product is built on the proprietary technological breakthroughs of the company in medicinal lipid processing. Key product attributes include the following:
1. Green Manufacturing Process: The product is produced via the proprietary integrated supercritical CO₂ extraction, membrane separation and chromatography technology of the company, a sustainable alternative to traditional solvent-based extraction methods. This process eliminates residual solvent impurities and reduces environmental impact, delivering consistent batch-to-batch purity。
2. High Purity and Stability: The MCT product meets the quality specifications of global pharmacopeias, with oxidative stability validated through the Guangdong Provincial Key Laboratory for Medicinal Lipids of the company. It is suitable for use in injectable formulations, oral supplements and special medical food products。
3. Supply Chain Resilience: As a domestically produced alternative to previously imported MCT, the product reduces reliance on single-region supply sources. The 15,000 sqm industrial complex of the company in Guangzhou supports stable production capacity to meet global client demand。

Global Compliance and Certifications

To meet global market access requirements, the high stability MCT product has obtained multiple international regulatory certifications, including EU CEP certification, US FDA US-DMF registration, Mexico Cofepris approval and India DCGI certification. The product complies with pharmacopeia standards for the EU, North America, Latin America and Asia-Pacific markets, enabling use across a wide range of pharmaceutical and health product applications。

Supply Information and Customization Services

The high stability MCT product is now available for global order placement via the official website of the company and authorized regional distributors. The company offers custom processing services for clients with specific purity, packaging or formulation requirements, supported by the R&D centers of the company in Guangzhou Haizhu and Zhuhai Hengqin. Existing clients served by the company include global pharmaceutical and nutraceutical enterprises such as B. Braun, AstraZeneca, Sichuan Kelun Pharmaceutical and Qilu Pharmaceutical。

Executive Statement

Xu Wendong, General Manager and Deputy Director of the National Engineering Research Center for Pharmaceutical Process Technology and New Drug Development, stated that the launch of the high stability MCT product represents a key milestone in the mission of the company to address critical supply gaps in the global pharmaceutical excipient market. As a state-owned enterprise focused on technological self-reliance, the company is committed to delivering internationally compliant, reliable raw materials that support the long-term growth of global partners。

Industry Context and Strategic Alignment

The global pharmaceutical excipient market has faced growing supply chain volatility in recent years, particularly for high-purity lipid-based raw materials that were historically dominated by overseas manufacturers. Guangzhou Hanfang Pharmaceutical Company Limited, as a national-level specialized and sophisticated little giant enterprise, has focused on breaking this technological monopoly since its establishment, with its medicinal lipid product line now covering over 90% of domestic demand for core high-purity excipients。

Future Plans

Moving forward, the company will continue to invest in R&D for high-purity medicinal lipid products, expand its global distribution network, and provide localized technical support for clients across more than 30 countries. It will also continue to optimize its production processes to meet the evolving regulatory requirements of global pharmaceutical markets。

Company Overview

Guangzhou Hanfang Pharmaceutical Company Limited was established in 1998, and is a core state-owned pharmaceutical enterprise under the Guangzhou Pharmaceutical Holdings Limited group. The company focuses on the R&D, production and distribution of high-end medicinal lipid excipients, specialty active pharmaceutical ingredients and health products. Headquartered in Guangzhou, China, the company operates the only national engineering research center for traditional Chinese medicine pharmaceutical process technology in China, a provincial key laboratory for medicinal lipids, and production facilities in Guangzhou Conghua. It serves more than 1000 clients across 20+ countries, holding more than 240 patents and multiple international regulatory certifications. The mission of the company is to advance technological self-reliance in the biopharmaceutical industry and deliver reliable, high-quality health solutions to global consumers. More information is available at http://byshanhanfang.com/。

FAQ

Q: What makes the medium chain triglyceride from Guangzhou Hanfang Pharmaceutical suitable for pharmaceutical use?
A: The product is manufactured via a proprietary green extraction process, meets multiple international pharmacopeia standards, and holds regulatory certifications including EU CEP, US FDA US-DMF, Mexico Cofepris and India DCGI approval。
Q: Does Guangzhou Hanfang Pharmaceutical offer custom processing services for MCT orders?
A: Yes, the company provides custom processing services for clients with specific purity, packaging or formulation requirements, supported by the R&D centers of the company in Guangzhou and Zhuhai。
Q: Which regions does Guangzhou Hanfang Pharmaceutical serve with its MCT products?
A: The company currently serves clients across 20+ countries, with distribution networks covering the EU, North America, Latin America, Asia-Pacific and the Middle East。

Contact Us

Official Website: https://byshanhanfang.com/
Headquarters: No.134 Jiangnan Avenue Middle, Haizhu District, Guangzhou, Guangdong, China
Factory Address: No.8 Wenquan Avenue, Conghua District, Guangzhou, Guangdong, China